छोड़कर सामग्री पर जाएँ

Divi#39;s Labs Q2 Preview: Earnings likely to improve sequentially on better margins, product mix

  • द्वारा
  • Latest News

A high base from the sales of COVID drug Molnupiravir and soft demand is likely to weigh the year-on-year growth for Divi#39;s Labs

Read More

​ A high base from the sales of COVID drug Molnupiravir and soft demand is likely to weigh the year-on-year growth for Divi#39;s Labs A high base from the sales of COVID drug Molnupiravir and soft demand is likely to weigh the year-on-year growth for Divi#39;s Labs  Moneycontrol Latest News Read More  

प्रातिक्रिया दे

आपका ईमेल पता प्रकाशित नहीं किया जाएगा. आवश्यक फ़ील्ड चिह्नित हैं *

hi_INहिन्दी